Alkermes Inc. plc (ALKS)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Alkermes Inc. plc (ALKS)
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Key Insights
Critical company metrics and information
Share Price
$31.18Market Cap
$5.04 BillionTotal Outstanding Shares
161.80 Million SharesTotal Employees
2,100Dividend
No dividendIPO Date
July 16, 1991SIC Description
Pharmaceutical PreparationsHomepage
https://www.alkermes.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $-488.97 Million |
Net Cash Flow From Operating Activities, Continuing | $355.96 Million |
Net Cash Flow From Investing Activities, Continuing | $-118.42 Million |
Net Cash Flow From Financing Activities, Continuing | $-488.97 Million |
Net Cash Flow From Operating Activities | $355.96 Million |
Net Cash Flow From Investing Activities | $-118.42 Million |
Net Cash Flow, Continuing | $-251.42 Million |
Net Cash Flow | $-251.42 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Operating Income/Loss | $312.58 Million |
Net Income/Loss Available To Common Stockholders, Basic | $333.35 Million |
Cost Of Revenue | $253.34 Million |
Income/Loss From Continuing Operations Before Tax | $332.18 Million |
Other Operating Expenses | $10.08 Million |
Research and Development | $261.08 Million |
Income Tax Expense/Benefit, Deferred | $-20.20 Million |
Gross Profit | $1.25 Billion |
Basic Average Shares | $166.77 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Parent | $333.35 Million |
Diluted Average Shares | $168.94 Million |
Benefits Costs and Expenses | $1.17 Billion |
Operating Expenses | $939.20 Million |
Selling, General, and Administrative Expenses | $668.03 Million |
Income Tax Expense/Benefit | $-54.78 Million |
Basic Earnings Per Share | $2.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss | $333.35 Million |
Revenues | $1.51 Billion |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income/Loss From Discontinued Operations Net Of Tax | $-53.61 Million |
Nonoperating Income/Loss | $19.60 Million |
Income/Loss From Continuing Operations After Tax | $386.95 Million |
Costs And Expenses | $1.19 Billion |
Diluted Earnings Per Share | $1.98 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Current Liabilities | $360.76 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity Attributable To Parent | $1.29 Billion |
Noncurrent Liabilities | $409.48 Million |
Other Non-current Assets | $365.69 Million |
Noncurrent Assets | $591.11 Million |
Wages | $55.90 Million |
Accounts Payable | $37.04 Million |
Liabilities | $863.18 Million |
Accounts Receivable | $367.21 Million |
Liabilities And Equity | $2.16 Billion |
Assets | $2.16 Billion |
Fixed Assets | $225.42 Million |
Equity | $1.29 Billion |
Current Liabilities | $453.70 Million |
Inventory | $191.09 Million |
Current Assets | $1.56 Billion |
Other Current Assets | $1.01 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Alkermes Inc. plc (ALKS)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.